Search Results
Promise of GPRC5D-targeted CAR-T therapies in multiple myeloma
GPRC5D-Targeted CAR T-Cell Therapy for RRMM: Phase 1 Study Outcomes of BMS-986393 (CC-95266)
GPRC5D and FCRH5 Targeted Therapies in Myeloma
BMS-986393: GPRC5D-targeted CAR for R/R myeloma
Clinical Activity of BMS-986393, a CAR T cell therapy directed at GPRC5D, in Pts with RRMM
Highlights at ASH 2022: the promise of T-cell redirecting therapies in multiple myeloma
Incorporating BCMA-targeted CAR-T therapy in the frontline treatment of multiple myeloma
CAR T-cells in Multiple Myeloma
CAR T Cell Therapy & Bispecifics: Cutting Edge Treatment in Myeloma | Dr. Joseph Mikhael
Highlights in multiple myeloma: improving access to CAR-T therapy, novel targets & future outlooks
Real-World CAR-T Data Update
Challenges associated with the use of off-the-shelf CAR-T products in multiple myeloma
